High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine

被引：1
|
作者：
Llibre, Josep M. [1 ,2 ,4 ]
Jou, Antoni [2 ,4 ]
Puig, Teresa [3 ]
机构：
[1] Univ Hosp Germans Trias, Infect Dis Div, Badalona, Spain
[2] Fight Infect Fdn, Badalona, Spain
[3] Irsi Caixa AIDS Res Inst, Badalona, Spain
[4] Hosp Univ Germans Trias, Infect Dis, Ctra Canyet S-N, Badalona 08916, Spain
来源：
CLINICAL INFECTIOUS DISEASES | 2024年 / 79卷 / 06期
关键词：
PLUS LAMIVUDINE; NAIVE ADULTS;
D O I：
10.1093/cid/ciae125
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1540 / 1541
页数：2
相关论文
共 50 条
  • [1] Dolutegravir/lamivudine/tenofovir/efavirenz/lamivudine/tenofovirInadvertent administration of dolutegravir/lamivudine/tenofovir, resistance to dolutegravir/lamivudine/tenofovir and efavirenz/lamivudine/tenofovir : case report
    Reactions Weekly, 2019, 1734 (1) : 187 - 187
  • [2] Why Tenofovir/Dolutegravir/Lamivudine if We Might Use Dolutegravir/Lamivudine
    Buzon-Martin, Luis
    Troya, Jesus
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [3] Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy
    Taiwo, Babafemi O.
    Quinones-Mateu, Miguel E.
    Smith, Kimberly
    Zheng, Lu
    Gulick, Roy
    Nyaku, Amesika N.
    Sax, Paul E.
    Ha, Belinda
    Kumwenda, Johnstone
    Olefsky, Maxine
    Godfrey, Catherine
    Wallis, Carole
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (04) : 254 - 255
  • [4] Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir
    George, Jomy M.
    Kuriakose, Safia S.
    Dee, Nicola
    Stoll, Pam
    Lalani, Tahaniyat
    Dewar, Robin
    Khan, Muhammad A.
    Rehman, Muhammad T.
    Grossman, Zehava
    Maldarelli, Frank
    Pau, Alice K.
    OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (10):
  • [5] Dolutegravir, abacavir and lamivudine as HIV therapy
    Vicente Fernandez-Montero, Jose
    Barreiro, Pablo
    Labarga, Pablo
    De Mendoza, Carmen
    Soriano, Vicente
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1051 - 1057
  • [6] Abacavir/dolutegravir/lamivudine overdoseHypokalaemia, lactic acidosis and mitochondrial toxicity following abacavir/dolutegravir/lamivudine intoxication: case report
    Reactions Weekly, 2018, 1695 (1) : 12 - 12
  • [7] Dolutegravir/lamivudine/tenofovirPeripheral neuropathy: case report
    Reactions Weekly, 2025, 2053 (1) : 132 - 132
  • [8] Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV
    Ikegaya, Kenichi
    Muramatsu, Takashi
    Sekiya, Ryoko
    Sekine, Yusuke
    Harada, Yuko
    Miyashita, Ryui
    Yamaguchi, Tomoko
    Ichiki, Akito
    Chikasawa, Yushi
    Bingo, Masato
    Yotsumoto, Mihoko
    Hagiwara, Takeshi
    Amano, Kagehiro
    Takeuchi, Hironori
    Kinai, Ei
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [9] Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance
    Nagami, Ellen H.
    Thakarar, Kinna
    Sax, Paul E.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (02):
  • [10] Dolutegravir/lamivudine/tenofovirImmune reconstitution inflammatory syndrome
    Reactions Weekly, 2024, 1996 (1) : 95 - 95
12345